BIOSIGHT TECHNOLOGY
BIOSIGHT TECHNOLOGY
Industry:
Artificial Intelligence Education Machine Learning
Founded:
2018-07-19
Address:
Kissimmee, Florida, United States
Country:
United States
Website Url:
http://www.biosight.technology
Total Employee:
1+
Status:
Closed
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Astrum.ai
Machine learning as a service
Combust.ML
Deploy Machine Learning Pipelines Easily
Founder
Official Site Inspections
http://www.biosight.technology
Unable to get host informations!!!
More informations about "Biosight Technology"
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger ...
Jul 27, 2023 Leveraging the combined capabilities and resources of both organizations will provide a truly unique opportunity to build a leading, publicly-traded oncology company with …See details»
BioSight - Crunchbase Company Profile & Funding
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. …See details»
BioSight - Innovative Cancer Therapeutics
BioSight's BST-236 is developed for acute myeloid leukemia treatment. BioSight is a pharmaceutical development company, developing novel cancer-targeted drugs. BioSight's BST-236 is developed for acute myeloid leukemia treatment. …See details»
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
“We are pleased to close the merger with Biosight which expands our product pipeline,” said Ken Berlin, President & CEO. “We have added aspacytarabine (BST-236), a novel antimetabolite, …See details»
Biosight Technology: Drug pipelines, Patents, Clinical trials - Synapse
Aug 10, 2023 Explore Biosight Technology with its drug pipeline, therapeutic area, technology platform, 3 news.See details»
Biosight Technology - Crunchbase Company Profile & Funding
964 Number of Organizations • $4.4B Total Funding Amount • 1,858 Number of Investors. Track . ... Biosight Technology is located in Kissimmee, Florida, United States. Who are Biosight …See details»
Advaxis and Biosight Announce Entry into Definitive Merger …
Jul 6, 2021 – Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute …See details»
Advaxis and Biosight Announce Entry into Definitive Merger
Jul 6, 2021 Advaxis, Inc. and Biosight Ltd., a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, …See details»
BioSight - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 3, 2024 Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological.See details»
Advaxis Agrees To Be Merged With Biosight; To Be Renamed …
Jul 6, 2021 The proposed merger will create a public company named Biosight Therapeutics that will prioritize the clinical advancement and commercialization of Biosight's lead product, …See details»
BioSight Company Profile 2024: Valuation, Investors ... - PitchBook
BioSight General Information Description. Developer of novel peptide-based drugs designed to provide therapeutics for hematological malignancies and disorders. The company's drugs …See details»
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed …
Nov 11, 2021 Combined company, to be named Biosight Therapeutics, expected to be well-positioned to leverage its compelling oncology therapeutics pipeline, strong cash position, and …See details»
Biosight Company Profile - Office Locations, Competitors ... - Craft
Biosight Summary. Company Summary. Overview. BioSight is a pharmaceutical company focused on the development of anti-cancer drugs and chemotherapy pro-drugs. Its main …See details»
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger …
Jul 27, 2023 Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the first half of 2024 …See details»
BioSight - Funding, Financials, Valuation & Investors - Crunchbase
Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 4. obfuscated. Total Funding Amount . ... How much funding has this organization raised over time? Show . …See details»
Advaxis and Biosight Announce Entry into Definitive Merger
Jul 6, 2021 White & Case and Horn & Co. are serving as legal counsel to Biosight. Management and Organization ... Advaxis’s ability to use and expand technology platforms to build a …See details»
Biosight Closes $46M Series C Financing to Advance Clinical …
Dec 2, 2020 Biosight’s lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with …See details»
Biosight Presents Updated Clinical Data from Ongoing Phase 2b …
BioSight Ltd. Fri, Jun 4, 2021, 8:00 AM 5 min read Complete remission rate of 39%, of which 63% were minimal residual disease negative, achieved in expanded data set in frontline acute …See details»
Biosight Announces Initiation of Phase 2 Clinical Trial of ...
Nov 12, 2021 U.S. Based Phase 2 Trial will Evaluate Aspacytarabine in Second Line Relapsed/Refractory MDS and AML across 18 Sites Builds Upon Ongoing Phase 2 …See details»
BioSight - Contacts, Employees, Board Members, Advisors & Alumni
BioSight has 5 current employee profiles, including CO-Founder & Chief Scientist Stela Gengrinovitch. BioSight has 1 board member or advisor, Aaron Sasson . ContactsSee details»